PTO/SB/08b (07-09)

U.S. Patent and Trademark Office. U.S. Def Arther to Trademark

Sut	slitule for form 1449/PTO				Complete ii raiowii
				Application Number	10/593,691-Conf. #3128
11	NFORMATION	N DI	SCLOSURE	Filing Date	December 4, 2006
S	TATEMENT I	3Y /	APPLICANT	First Named Inventor	Ayumu KURIMOTO
				Art Unit	1624
	(Use as many sh	eets a	s necessary)	Examiner Name	M. L. Berch
heet	1	of	3	Attorney Docket Number	0020-5516PUS1

			U.S. PA	TENT DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA*	US-2002/0068745A1	06-2002 06-2002	Levy et al	
	AB*				al
	AC*		09-2007		
	AD*	US-2005/54590	93-2005 97-2004	Averette	
	AE*	US-2004/0132748A1	07-2004	Isobe	
	AF*	US-2009/0192153A1	07-2009	Hashimoto et al.	

			FOREI	GN PATENT	DOCUMENTS			1
	Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Raleveni		1
	Initials*	No.1	Country Code ³ -Number ⁴ -Kind Code ⁵ (If known)	MM-DD-YYYY	Applicant of Cited Document	Pesseges Or Relevant Figures Appear	T°	ŀ
		BA	EP-1908480-A1	04-09-2008	Riken			1
	***************************************	DD	JP-10-301333AT	02-10-1996	Blochem Pirami.		Abs	ļ
		B9	JP 49 597474	07.14.1000	Chirogolopeo Ltd		Ahe	
		-00	JP-2007-504282					
		DE	₩P-947422					
		DC.	ID 0 007440				Abs	
	-	Di	UT 0 001 4 10	***************************************			Abs	-
		<u>BC</u>	JP 0-367451	***************************************			Abo	
		B++	W9-1008/01119-A1	01-15-1999	Vapan Ericing Ourp.		Abs	
		DI-	WO-2002/005005-A4	10-01-2002	Japan Energy Sorp.		A	
		<u> </u>	14/0 0000/40070444	12.07.2000	Riken		7103	
		7346	W-00001011010171	AE OF E000	TAMOR		1,000	A-COCCOCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC
		DIC	110-2004/011401				Abo.	
_		DL	VVO-2004/029054	04-08-2694			Abs	
		BM	WG-2085/802002-A1	10-00-2000	Sumitomo Pharma et al.		ADS	
		DN	WO 2006/002803 A1		Sumitemo Phanna et al		**	
- 1			WO-2006/117670-A1		Pfizer Ltd et al		AUS	
		BP	WO-2007/024707-A2	03-01-2007	Univ California et al			
-[BQ	WO-2007/031726	03-2007				
- [BR	WO-2007/034173	03-2007			\neg	

"EXAMENER: mild of reference considered, whether or not distation is no conformance with INETP POD. Dave the Record colors of not in conformance and not considered for location operation of the conformance and not considered for the conformance of the record construction of the conformance of the record of th

/Mark Berch/ (07/06/2010)

Examiner

Signature

Date

Considered

PTO/SB/08b (07-09)

Approved for use through 07/31/2012 OMB 0651-0031
U.S. Patent and Transmit Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a cotlection information unlines it contains a set of OMB certific number.

Substit	ute for form 1449/PT	0			Complete if Known		
				Application Number	10/593,691-Conf. #3128		
INF	ORMATIC	ON DI	SCLOSURE	Filing Date	December 4, 2006		
ST	ATEMENT	BY	APPLICANT	First Named Inventor	Ayumu KURIMOTO		
				Art Unit	1624		
	(Use as many sheets as necessary)			Examiner Name	M. L. Berch		
heet	2	of	3	Attorney Docket Number	0020-5516PUS1		

		FOREI	GN PATENT	DOCUMENTS		
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines, Where Relevant	
Initials*	No.1	Country Code ² -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Passages Or Relevant Figures Appear	T ⁶
				Dainingan Sumitama Pharma		
	85	VVO-2007/034817-A1	03-29-2007	Co et al.		Abs
	вт	WO-2007/034881-A1	03-29-2007	Dainippon Sumitomo Pharma Co et al.		
	BU	WO-2007/034882-A1	03-29-2007	Dainippon Sumitomo Pharma Co et al.		
	BV	WO-2007/034916-A1	03-29-2007	Dainippon Sumitomo Pharma Co et al.		
	DIA/	WO 2007/034047 A4	02.20.2007	Dainippon Sumitomo Pharma		
			AG EG EGO	Co et al.		705
	BX	WO-2008/071976-A1	06-19-2008	Astrazeneca Ab et al.		
	BY	WO-2008/114006-A2	09-25-2008	Astrazeneca Ab et al.		
	BZ	WO-2008/114008-A1	09-25-2008	Astrazeneca Ab et al.		
		1				

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²				
	CA	Korc, M., "Pathways for aberrant angiogenesis in pancreatic cancer," Biomed Central, Vol 2, No 8, pp 1-8 (2003)	Г				
	СВ	Zalutsky, MR, "Targeted radiotherapy of brain tumours," British J. of Cancer, Vol 90, pp 1469-1473 (2004)					
	СС	Drazen, J.M., "Surgery for Emphysema-Not for Everyone," New Eng. J. Med., Vol 345, No 15, pp 1126-1128 (2001)	Г				
	CD	Mogulkoc, N., et al., "Pulmonary function in Idiopathic Pulmonary Fibrosis and Referral for Lung Transplantation," Am. J. Respir. Crit. Care Med., Vol 164, pp 103-108 (2001)					
	CE	Palmer, S., et al., "Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development," AIDS, Vol 13, pp 661-667 (1999)					
	CF	Fridkin, SK, "Vancomycin-Intermediate and –Resistant Staphylococcus aureus: What the Infectious Disease Specialist Needs to Know," Clinical Infectious Diseases, Vol 32, pp 108-115 (2001)					

Examiner		Date
Signature	/Mark Berch/ (07/06/2010)	
Oignature	/Mark Derch 107/00/2010)	Considered

"EXAMINER, Initial Enforcement consistents, whether or not distalon in a conformance with INECP POD. Dow for Brough citation if not in conformance and not conserved, include only on the form with international communication beginnism." (CTEN DAY TO those applications) which are marked with a registration of the CTEN DAY TO CTEN

Approved for use through 07/31/2022. OMB 0861-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMENT

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMENT

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless to contains a valid Office on the formation unless of the contains a valid Office of the Insured.

Substitu	te for form 1449/F	то		Complete if Known		
				Application Number	10/593,691-Conf. #3128	
INF	ORMATI	ON DISC	CLOSURE	Filing Date	December 4, 2006	
STA	TEMEN	T BY AF	PLICANT	First Named Inventor	Ayumu KURIMOTO	
				Art Unit	1624	
	(Use as many sheets as necessary)			Examiner Name	M. L. Berch	
Sheet	sheet 3 of 3		Attorney Docket Number	0020-5516PUS1		

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, caladig, etc.), date, page(s), volume-issu number(s), publisher, city and/or country where publisher.			
	CG	Lee, J., et al., *Activation of anti-hepatitis C virus responses via Toll-like receptor 7," PNAS, Vol 103, No 6, pp 1828-1833 (2006)		
	СН	Kurimoto, A., et al., "Synthesis and Biological Evaluation of 8-Oxoadenine Derivatives as Toll- like Receptor 7 Agonists Introducing the Antedrug Concept," J. Med. Chem., Vol 53, No 7, pp 2994-2972 (2010)		
	CI	2009-03-26 Office Action for Russian Application 2006137706 w/English Translation	·	
	CJ	2009-08-21 Office Action for Russian Application 2006137706 w/English Translation	_	
	CK	2009-03-25 New Zealand Examination Report for Application 549903	-	
	CL	2010-01-14 New Zealand Examination Report for Application 549903		
	CM	2009-11-17 Office Action for Japanese Application 2006-511501 w/English Translation		
	CN	2009-12-10 Office Action for Israeli Application 177518 in English		
	CO	2006-09-26 Office Action for Egypt Application PCT923/2006 w/English Translation	\vdash	
	CP	2008-04-25 Office Action for Chinese Application 200580009706.3 w/English Translation		
	CQ	2010-01-15 Office Action for Malaysia Application PI20051334 in English		
	CR	2010-03-11 Office Action for US Application 10/594,074	-	
	CS	2008 PCT/JP2006/318603 IPER for Application 12/067,649		
	CT	2009-09-22 IPER for Application 12/532,007		
	CU	PCT/JP2008/055088 IPER for Application 12/531,867		

Examiner	7.4 1 7 7 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2	Date	
Signature	/Mark Berch/ (07/06/2010)	Considered	
		Considered	

EXAMER: Initial inference considered, whether or not obtain is in continuous with MEEP DID. Dever ten through citation I in all or conformance and not considered. Initial copy of 18 fist more with commencation beginning. **CETE No.Dever produced the continuous and not to the Cite No. on not expelled content of 27 GFT 5.196(9)(2)(6)) because that application was filed affect June 30, 2020 or its available in pits I in FIV. **Applicant's united continuous and the content of the c